Ex vivo delivery of recombinant IL-10 to human donor lungs
Gene therapy remains superior as it allows for continued production of IL-10 within the alveoli where it has the potential to continuously act on alveolar macrophages and epithelial cells in a paracrine fashion.
Authors
- Dirk Wagnetz
- Riccardo Bonato
- Jonathan Yeung (ORCID: https://orcid.org/0000-0001-5759-3028)
- S. Juvet (ORCID: https://orcid.org/0000-0002-7243-556X)
- Terumoto Koike (ORCID: https://orcid.org/0000-0002-7470-8867)
- Tiago Machuca (ORCID: https://orcid.org/0000-0002-0748-7590)
- Shaf Keshavjee (ORCID: https://orcid.org/0000-0003-4547-8094)
- Marcelo Cypel (ORCID: https://orcid.org/0000-0001-5652-1938)
- Mingyao Liu (ORCID: https://orcid.org/0000-0002-9188-8417)
Institutions
- University Health Network (CA)
Publication Details
- Journal
- JHLT Open
- Published
- 2024-12-06
- DOI
- https://doi.org/10.1016/j.jhlto.2024.100192
- Primary Topic
- Transplantation: Methods and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Canadian Institutes of Health Research